LifeSci Capital initiates BlossomHill Therapeutics at Outperform
LifeSci Capital initiated BlossomHill Therapeutics with an Outperform rating and set a $32.00 price target per share, per Benzinga via TradingView News.
Ratings actions GMT) BlossomHill Therapeutics Initiated at Outperform by LifeSci CapitalRatings actions